Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Birmingham Post
Birmingham Post
Tom Keighley

Gateshead's Shield Therapeutics awaits Canadian regulatory approval for iron deficiency drug

Shield Therapeutics is hopeful it will be able to sell its lead drug product in Canada after health authorities in the country accepted it for regulatory review.

The Gateshead firm told investors that Health Canada, the government department responsible for national health policy, will review its Accrufer drug following a 'New Drug Submission' by its licensing partner KYE Pharmaceuticals Inc. An outcome is expected mid-2023 and if successful will allow KYE.

Shield said it is due to receive a £250,000 milestone payment if it gets regulatory approval, and the firm is eligible for a further £600,000 in milestone payments when it meets sales targets. Through its licensing deal with KYE announced earlier this year, Shield will also receive double-digit royalties on net sales of Accrufer.

Read more: go here for more North East business news

In June, Shield reported it had secured a $10m shareholder loan following a strong start to the year on the back of a "transformational" 2021. At the time, the firm said it had gained FDA approval to raise Accrufer’s product shelf life from 24 to 36 months, giving additional flexibility in manufacturing and storage timelines.

Last year it launched Accrufer in the US following a four-year build up in which included FDA challenges.


Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.